You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCNSL

Showing 1 - 25 of 120
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
  • PCNSL
  • Milan, Italy
    Ospedale San Raffaele
Mar 13, 2023

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

Micro and Macroscopic Level of Primary Central Nervous System

Active, not recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Tumor samples and MRI
  • Paris, France
    Groupe Hospitalier La Pitié Salpêtrière
Feb 17, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

Primary CNS Lymphoma (PCNSL) Trial in Zhengzhou (HD-MTX-Ara-C regimen, FTD regimen)

Completed
  • Primary CNS Lymphoma (PCNSL)
  • HD-MTX-Ara-C regimen
  • FTD regimen
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
Mar 2, 2022

Factors in Patients With Primary Central Nervous System Lymphoma

Recruiting
  • PCNSL
  • Survival Analysis
  • prognostic marker
  • Zhengzhou, Henan, China
    Zhengzhou university
Dec 12, 2021

Primary CNS Lymphoma Trial in Moscow (Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide)

Recruiting
  • Primary CNS Lymphoma
  • Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
  • Moscow, Russian Federation
    Nathional Medical Research Center for Hematology
Jun 16, 2022

Primary CNS Lymphoma Trial in Seoul (Rituximab, lenalidomide)

Recruiting
  • Primary CNS Lymphoma
  • Rituximab, lenalidomide
  • Seoul, Korea, Republic of
    Samsung Medical Center
Feb 4, 2022

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +2 more
May 19, 2022

Part A: Relapsed or Refractory Primary CNS Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL Trial in United

Recruiting
  • Part A: Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL
  • Duarte, California
  • +29 more
Jun 15, 2022

PCNSL, Secondary CNS Lymphoma Trial in Beijing, Guangzhou, Shanghai (ICP-022)

Recruiting
  • PCNSL
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +4 more
Jul 28, 2021

Primary CNS Lymphoma Trial in Stuttgart (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix,

Recruiting
  • Primary Central Nervous System Lymphoma
  • Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
  • Control intervention: four courses of MATRix
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Feb 15, 2022

Lymphoma, B-Cell Trial in Taipei (non-intervention)

Recruiting
  • Lymphoma, B-Cell
  • non-intervention
  • Taipei, Taiwan
    National Taiwan University Hospital
Jun 14, 2021

Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guangzhou (Orelabrutinib, Thiotepa)

Not yet recruiting
  • Refractory and Relapsed Primary CNS Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Aug 19, 2021

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
  • +2 more
Aug 11, 2022

CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma Trial in Basking Ridge, Commack, New York (Rituximab, Methotrexate,

Active, not recruiting
  • CNS Lymphoma
  • +2 more
  • Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
  • Basking Ridge, New Jersey
  • +2 more
Jan 27, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial (F520)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • (no location specified)
Oct 19, 2020